TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
施金元SHIH, JIN-YUAN
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
發表文獻
41筆
1
Chang, G. C., Lam, D. C. L., Tsai, C. M., Chen, Y. M., Shih, J. Y., Aggarwal, S., Wang, S. H., Kim, S. W., Kim, Y. C., Wahid, I., Li, R. B., Lim, D. W. T., Sriuranpong, V., Chan, R. T. T., Lorence, R. M., Carriere, P., Raabe, C., Cseh, A., & Park, K. (2021). Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. International Journal of Clinical Oncology, 26(5), 841-850. https://doi.org/10.1007/s10147-021-01869-0
2
Chung, K. P., Huang, Y. L., Chen, Y. J., Juan, Y. H., Hsu, C. L., Nakahira, K., Huang, Y. T., Lin, M. W., Wu, S. G., Shih, J. Y., Chang, Y. L., & Yu, C. J. (2021). Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1. Molecular Oncology, 15(2), 560-578. https://doi.org/10.1002/1878-0261.12843
3
Hsu, C. L., Tsai, T. H., Huang, C. K., Yang, C. Y., Liao, W. Y., Ho, C. C., Ruan, S. Y., Chen, K. Y., Shih, J. Y., & Yang, P. C. (2021). Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer. Lung Cancer, 156, 50-58. https://doi.org/10.1016/j.lungcan.2021.04.014
4
Huang, J. W., Kuo, C. H., Kuo, H. C., Shih, J. Y., Tsai, T. W., & Chang, L. C. (2021). Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel. Plos One, 16(3), Article e0248942. https://doi.org/10.1371/journal.pone.0248942
5
Huang, J. W., Kuo, C. H., Kuo, H. C., Shih, J. Y., Tsai, T. W., & Chang, L. C. (2021). Differences in Fatty Acid Oxidation between Nab-Paclitaxel- and Solvent-Based Paclitaxel-Treated A549 Cells Based on Metabolomics. Acs Omega, 6(8), 5138-5145. https://doi.org/10.1021/acsomega.0c04385
6
Huang, Y. S., Chen, J. L. Y., Chen, H. M., Yeh, L. H., Shih, J. Y., Yen, R. F., & Chang, Y. C. (2021). Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer. Bmc Cancer, 21(1), Article 348. https://doi.org/10.1186/s12885-021-08064-4
7
Huang, Y. S., Niisato, E., Su, M. Y. M., Benkert, T., Hsu, H. H., Shih, J. Y., Chen, J. S., & Chang, Y. C. (2021). Detecting small pulmonary nodules with spiral ultrashort echo time sequences in 1.5 T MRI. Magnetic Resonance Materials in Physics Biology and Medicine, 34(3), 399-409. https://doi.org/10.1007/s10334-020-00885-x
8
Liang, S. K., Keng, L. T., Chang, C. H., Wen, Y. F., Lee, M. R., Yang, C. Y., Wang, J. Y., Ko, J. C., Shih, J. Y., & Yu, C. J. (2021). Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort. Frontiers in Oncology, 10, Article 590356. https://doi.org/10.3389/fonc.2020.590356
9
Lu, S., Shih, J. Y., Jang, T. W., Liam, C. K., & Yu, Y. F. (2021). Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Advances in Therapy, 38(5), 2038-2053. https://doi.org/10.1007/s12325-021-01696-9
10
Nishio, M., Seto, T., Reck, M., Garon, E. B., Chiu, C. H., Yoh, K., Imamura, F., Park, K., Shih, J. Y., Visseren-Grul, C., Frimodt-Moller, B., Zimmermann, A., Homma, G., Enatsu, S., Nakagawa, K., & Investigators, R. S. (2021). Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY (vol 111, pg 4510, 2020). Cancer Science, 112(5), 2064-2064. https://doi.org/10.1111/cas.14922
